Citi analyst Yigal Nochomovitz tells investors that Apellis management gave an "unambiguous" answer to him when asked about Dr. Baumal’s access in pre-employment discussions that Baumal has "seen pretty much everything at this point," including the back and forth with the FDA, which he thinks "speaks volumes" about her belief in GA approval and decision to join the company as its CMO. Nochomovitz, who would recommend buying Apellis shares amid the dip today, reiterates a Buy rating, $86 price target and the stock’s position on Citi’s U.S. Focus List. Apellis shares are down $2.76, or nearly 6%, to $47.32 in afternoon trading.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on APLS:
- Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
- Apellis appoints Baumal as Chief Medical Officer
- Vaxcyte named as Top Pick, added to Conviction list at Needham
- Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Wells Fargo downgrades Apellis to Equal Weight, lowers price target to $58